<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993861</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00070924</org_study_id>
    <nct_id>NCT02993861</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Anti-epileptic Drugs in Obese Children</brief_title>
  <official_title>Pharmacokinetics of Anti-epileptic Drugs in Obese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multi-center, open-label clinical trial. Study's purpose is to
      characterize the pharmacokinetics and safety of four oral anti-epileptics drugs
      (levetiracetam, valproic acid [divalproex sodium ER or immediate release formulation if
      inadequate enrollment}, topiramate, and oxcarbazepine) in a non-randomized sample of obese
      children and adolescents. The study's duration will be up to eleven days (up to seven days of
      screening and four days of pharmacokinetic sampling). Eligible participants ages 2 to 18
      years will be identified through outpatient clinic schedules and inpatient admissions at each
      clinic site. Participants receiving at least one of the study drugs per local standard of
      care will have pharmacokinetic concentrations in plasma drawn according to the specific
      dosing schedule for each drug. Other study measures include demographics, BMI, waist/hip
      ratio, medical history, concomitant medication history, documentation of study drug oral
      intake, adverse effects, and physical examination. The sample size will include 24
      participants for each anti-epileptic drug (total 96).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics area under the curve</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics maximum concentration</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics time to reach maximum concentration</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics oral apparent volume of distribution</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics half life</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics oral apparent clearance</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics absorption rate constant</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Up to 11 days (up to 7 days of screening and 4 days of pharmacokinetic sampling)</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Epilepsy</condition>
  <condition>Obese</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <description>Children with epilepsy who are treated with levetiracetam per local standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic Acid</arm_group_label>
    <description>Children with epilepsy who are treated with valproic acid per local standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <description>Children with epilepsy who are treated with topiramate per local standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxcarbazepine</arm_group_label>
    <description>Children with epilepsy who are treated with oxcarbazepine per local standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-epileptics</intervention_name>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_label>Valproic Acid</arm_group_label>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_label>Oxcarbazepine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with epilepsy who are inpatients in local hospital or managed in outpatient
        settings - community sample.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 years to &lt; 18 years at the time of enrollment

          -  BMI ≥ 95th percentile for age and sex, based on CDC recommendations

          -  Informed consent/HIPAA from the parent/legal guardian and assent (as applicable)

          -  Receiving ≥ 1 of the study drugs per local standard of care

        Exclusion Criteria:

          -  Known pregnancy as determined via interview or test results, if available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kanecia Zimmerman, MD, MPH</last_name>
    <phone>919-668-8651</phone>
    <email>kanecia.obie@dm.duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barrie Harper</last_name>
    <phone>919-668-8291</phone>
    <email>barrie.harper@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Austin Drake</last_name>
      <phone>720-777-4719</phone>
      <email>austin.drake@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Charuta Joshi, MD</last_name>
      <phone>1-720-777-6895</phone>
      <email>charuta.joshi@childrenscolorado.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nemours Alfred I. DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramany John</last_name>
      <phone>302-298-7521</phone>
      <email>ramany.john@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Marisa Meyer, MD</last_name>
      <phone>1-302-651-4021</phone>
      <email>marisa.meyer@nemours.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Childrens Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sims Christopher</last_name>
      <phone>404-785-8798</phone>
      <email>christopher.sims@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Ton DeGrauw, MD</last_name>
      <phone>1-404-785-4446</phone>
      <email>ton.degrauw@choa.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fearn</last_name>
      <phone>312-227-6280</phone>
      <email>lfearn@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>William Muller, MD</last_name>
      <phone>312-503-3218</phone>
      <email>wjmuller@northwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Louisville Norton Childrens Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Simeon</last_name>
      <phone>502-629-5820</phone>
      <email>theresa.simeon@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arpita Lakhotia, MD</last_name>
      <phone>1-502-629-5820</phone>
      <email>arpita.lakhotia@louisville.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shradhdha Joshi</last_name>
      <phone>919-966-9051</phone>
      <email>snjoshi@neurology.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yael Shiloh-Malawsky, MD</last_name>
      <phone>919-966-2922</phone>
      <email>yaelm@neurology.unc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanecia Zimmerman, MD</last_name>
      <phone>919-668-8651</phone>
      <email>kanecia.obie@dm.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Harward Melissa</last_name>
      <phone>919-668-3910</phone>
      <email>melissa.harward@dm.duke.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Coastal Children's Services</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arielle Lapid</last_name>
      <phone>910-667-5483</phone>
      <email>arielle.lapid@ccneo.net</email>
    </contact>
    <contact_backup>
      <last_name>Sasidharan Taravath, MD</last_name>
      <phone>1-910-667-5165</phone>
      <email>sasi.taravath@coastalchildrensservices.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kira Clark</last_name>
      <phone>503-418-8112</phone>
      <email>clarki@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amira Al-Uzri</last_name>
      <phone>1-503-494-6956</phone>
      <email>aluzria@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Arnold, MD</last_name>
      <phone>214-456-8242</phone>
      <email>susan.arnold@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Kelton</last_name>
      <phone>206-987-5539</phone>
      <email>megan.kelton@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Flynn, MD</last_name>
      <phone>1-206-987-2524</phone>
      <email>joseph.flynn@seattlechildrens.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

